InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies

  • Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids
  • Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases
  • Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder

Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has no approved treatments, according to the Dystrophic Epidermolysis Bullosa Research Association of America. Researchers at InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), however, hope to treat this unmet medical need with a topical drug called INM-750 that includes multiple biosynthesized cannabinoids as its active ingredients.

Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases. The company’s biosynthesis platform works by inserting the plant’s DNA into E. coli bacteria that has the internal ability to…


More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

Leave a Reply